爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

laboratorios liconsa s.a. - valsartaan - õhukese polümeerikattega tablett - 40mg 98tk; 40mg 280tk; 40mg 56tk; 40mg 14tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

laboratorios liconsa s.a. - valsartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 80mg+12,5mg 280tk; 80mg+12,5mg 98tk; 80mg+12,5mg 28tk; 80mg+12,5mg 14tk; 80mg+12,5mg 56tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

laboratorios liconsa s.a. - venlafaksiin - toimeainet prolongeeritult vabastav tablett - 300mg 56tk; 300mg 500tk; 300mg 60tk; 300mg 98tk; 300mg 10tk; 300mg 20tk; 300mg 100tk; 300mg 28tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

norameda uab - pramipeksool - tablett - 0,18mg 30tk; 0,18mg 100tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

laboratorios liconsa s.a. - losartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 50mg+12,5mg 98tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

laboratorios liconsa s.a. - losartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 100mg+25mg 28tk

爱沙尼亚 - 爱沙尼亚文 - Ravimiamet

sandoz pharmaceuticals d.d. - tsetirisiin - õhukese polümeerikattega tablett - 10mg 30tk

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

accord healthcare s.l.u. - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastilised ained - breast cancermetastatic breast cancer zercepac is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. eelnev keemiaravi peab olema kantud vähemalt anthracycline ja taxane välja arvatud juhul, kui patsientidele ei sobi nende ravi. hormooni retseptori positiivne patsientidel peab olema ebaõnnestunud hormoonravi, välja arvatud juhul, kui patsientidele ei sobi nende ravi.                      in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. koos docetaxel raviks nendel patsientidel, kes ei ole saanud keemiaravi oma metastaatilise haiguse. kombinatsioonis aromataasi inhibiitoriga ravi postmenopausis patsientidel hormoon-retseptor positiivne mbc, mis ei ole varem ravitud trastuzumab. early breast cancer zercepac is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). pärast operatsiooni, kemoteraapiat (neoadjuvant-või abiaine) ja kiiritusravi (kui on kohaldatav). järgmised abiaine keemiaravi koos doxorubicin ja tsüklofosfamiidiga kombinatsioonis paclitaxel või docetaxel. koos abiaine keemiaravi, mis koosneb docetaxel ja carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay. metastatic gastric cancer zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. zercepac should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory sish or fish result, or by an ihc 3+ result. täpseid ja valideeritud analüüsi meetodeid tuleks kasutada.

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - sead - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

欧盟 - 爱沙尼亚文 - EMA (European Medicines Agency)

the medicines company uk ltd - bivalirudin - Äge koronaarsündroom - antitrombootilised ained - angiox on näidustatud on antikoagulant täiskasvanud patsientidel toimumas perkutaanse koronaarse interventsiooni (pci), sealhulgas patsiendid, kellel on st-segmendi-elevatsiooniga müokardiinfarkti (stemi) toimumas primaarne pci. angiox on näidustatud ka ravi täiskasvanud patsientidel, kellel ebastabiilne stenokardia / mitte-st-segmendi-elevatsiooniga müokardiinfarkti (ua / nstemi) planeeritud kiiresti või varajane sekkumine. angiox tuleb manustada koos aspiriini ja clopidogrel.